Introduction
The unexpected 30% increase in customer support tickets for Thermo Fisher Scientific's Invitrogen Countess 3 Automated Cell Counter over the past month is a significant issue that requires immediate attention. This surge in support requests could indicate underlying problems with the product, user experience, or external factors affecting its performance. To address this challenge, I'll employ a systematic approach to identify, validate, and resolve the root cause while considering both short-term fixes and long-term strategic implications.
This analysis follows a structured approach covering issue identification, hypothesis generation, validation, and solution development.
Step 1
Clarifying Questions (3 minutes)
Why it matters: Software updates can introduce bugs or usability issues. Expected answer: Yes, a major update was released 6 weeks ago. Impact on approach: If yes, we'd focus on post-update issues; if no, we'd look at hardware or external factors.
Why it matters: This could indicate onboarding problems or a learning curve issue. Expected answer: The ratio of new users reporting issues has increased by 40%. Impact on approach: If new users are disproportionately affected, we'd focus on onboarding and user education.
Why it matters: This could point to specific product areas or functionalities causing problems. Expected answer: 60% of tickets mention issues with cell viability calculations. Impact on approach: We'd prioritize investigating and fixing the most commonly reported issues.
Why it matters: Changes in sample types could affect the counter's performance. Expected answer: No significant changes reported in sample types. Impact on approach: If yes, we'd look into adapting the product for new sample types; if no, we'd focus on internal factors.
Why it matters: This could explain the increase if it's due to changes in measurement rather than actual issues. Expected answer: No changes to the ticketing system or processes. Impact on approach: If yes, we'd need to re-evaluate our metrics; if no, we can trust the reported increase.
Practice similar questions
Subscribe to access the full answer